Ingenus FDA Tuesday, November 24, 2020 0.00 Neutral

FDA Approves SCOPOLAMINE — Ingenus Pharmaceuticals, LLC

# FDA Approves Ingenus Pharmaceuticals' Generic Scopolamine Transdermal Patch Ingenus Pharmaceuticals, LLC has received FDA approval for its generic scopolamine transdermal patch under ANDA 212342, expanding treatment options for motion sickness and nausea while potentially increasing price competition in the transdermal patch market. The approval is expected to provide patients with a more affordable alternative to branded formulations and strengthen Ingenus's position in the generic pharmaceutical space.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day